Studio su pembrolizumab/vibostolimab in combinazione con chemioradioterapia concomitante seguita da pembrolizumab/vibostolimab rispetto a chemioradioterapia concomitante seguita da durvalumab in partecipanti con carcinoma polmonare non a piccole cellule in stadio III

This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab versus cCRT followed by durvalumab in participants with unresectable, locally